Oragenics
NYSE: OGENTampa, US · Florida corporation
Oragenics develops treatments for concussion and traumatic brain injury, focusing on clinical development of therapeutic candidates. The company combines neuroscience expertise with healthcare operational leadership to advance solutions for brain injury treatment.
Founders & leadership
AJ
Alan JoslyninChief Executive Officer2016–2021
MS
Michael SullivanExecutive
JH
Janet HuffmanChief Executive Officer & Chief Financial Officer
JP
James P. KellyChief Medical Officer
WP
William PeacockChief Clinical Officer
Board
RK
Robert KoskiBoard director
FT
Frederick TellingBoard director
AD
Alan DuntonBoard director
CP
Charles PopeBoard director
Reported raises · per SEC filings
Form D private placements$19.9M disclosed across 6 of 8 rounds · 2016–2026
▶$850KraisedAug 2023 · 2 investors · BiotechnologyRule 506(b)
▶$850KraisedAug 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan DuntonDirector
- Frederick TellingDirector
- Kimberly MurphyExecutive Officer, Director
- Janet HuffmanExecutive Officer
- Charles PopeDirector
- Robert KoskiDirector
- Offering amount
- $850K
- Amount sold
- $850K
- Minimum investment
- $100K
- First sale
- Aug 2023
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$4.6MraisedMay 2020 · 1 investors · BiotechnologyRule 506(b)
▶$4.6MraisedMay 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PopeDirector
- Michael SullivanExecutive Officer
- Robert KoskiDirector
- Frederick TellingDirector
- Alan JoslynExecutive Officer, Director
- Alan DuntonDirector
- Amount sold
- $4.6M
- First sale
- May 2020
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$1.8MraisedApr 2018 · 2 investors · BiotechnologyRule 506(b)
▶$1.8MraisedApr 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan JoslynExecutive Officer, Director
- Frederick TellingDirector
- Charles PopeDirector
- Robert KoskiDirector
- Alan DuntonDirector
- Michael SullivanExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- Sales commissions
- $144K
- Placement agents
- LADENBURG THALMANN & CO. INC.
- First sale
- Apr 2018
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$6.7MraisedNov 2017 · 5 investors · BiotechnologyRule 506(b)
▶$6.7MraisedNov 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PopeDirector
- Michael SullivanExecutive Officer
- Frederick TellingDirector
- Robert KoskiDirector
- Alan DuntonDirector
- Alan JoslynExecutive Officer, Director
- Offering amount
- $6.7M
- Amount sold
- $6.7M
- First sale
- Nov 2017
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$1.3MraisedMay 2017 · 3 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMay 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert KoskiDirector
- Frederick TellingDirector
- Alan DuntonDirector
- Charles PopeDirector
- Michael SullivanExecutive Officer
- Alan JoslynExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.3M
- First sale
- May 2017
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$4.7MraisedJul 2016 · 3 investors · BiotechnologyRule 506(b)
▶$4.7MraisedJul 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frederick TellingDirector
- Alan DuntonDirector
- Alan JoslynExecutive Officer, Director
- Michael SullivanExecutive Officer
- Robert KoskiDirector
- Charles PopeDirector
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- Jun 2016
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Robinhood46 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha30 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall St30 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies competing with Oragenics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $256.7K |
| National Science Foundation | Phase II | 2008 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $100K |
| National Science Foundation | Phase I | 2006 | $99.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $100K |
| National Science Foundation | Phase I | 2004 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Phase IIa Concussion Trial, Provides FDA and Listing Updates - InvestorWire (IW)investorwire.com · Aug 2026Frequently asked questions
- What does Oragenics do?
- Oragenics develops treatments for concussion and traumatic brain injury, focusing on clinical development of therapeutic candidates. The company combines neuroscience expertise with healthcare operational leadership to advance solutions for brain injury treatment.
- How much funding has Oragenics raised?
- Oragenics has disclosed $19.9M raised across 6 of its 8 known rounds.
- Where is Oragenics headquartered?
- Oragenics is headquartered in Tampa, US.